Bicillin Cr
NDC Package 68258-8910-2

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was inactivated by the FDA.

Bicillin Cr is to reduce the development of drug-resistant bacteria and maintain the effectiveness of Bicillin C-R and other antibacterial drugs, Bicillin C-R should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. Marketed by Dispensing Solutions, Inc., this product is identified by NDC 68258-8910 and is authorized under FDA application NDA050138.

Identification & Billing

NDC Package Code
68258-8910-2
Package Description
2 mL in 1 SYRINGE
Product Code
68258-8910
11-Digit Billing Format
68258891002
RxNorm Crosswalk
  • RxCUI: 731538 - penicillin G benzathine / penicillin G procaine 1,200,000 UNT (600,000 UNT/ 600,000 UNT) in 2 ML Prefilled Syringe
  • RxCUI: 731538 - 2 ML penicillin G benzathine 300000 UNT/ML / penicillin G procaine 300000 UNT/ML Prefilled Syringe
  • RxCUI: 731538 - penicillin G benzathine 600,000 UNT / penicillin G procaine 600000 UNT per 2 ML Prefilled Syringe
  • RxCUI: 731541 - BICILLIN C-R 1,200,000 UNT in 2 ML Prefilled Syringe
  • RxCUI: 731541 - 2 ML penicillin G benzathine 300000 UNT/ML / penicillin G procaine 300000 UNT/ML Prefilled Syringe [Bicillin]

Clinical Specifications

Proprietary Name
Bicillin Cr
Dosage Form
-
Usage Information
To reduce the development of drug-resistant bacteria and maintain the effectiveness of Bicillin C-R and other antibacterial drugs, Bicillin C-R should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.This drug is indicated in the treatment of moderately severe infections due to penicillin-G-susceptible microorganisms that are susceptible to serum levels common to this particular dosage form. Therapy should be guided by bacteriological studies (including susceptibility testing) and by clinical response.Bicillin C-R is indicated in the treatment of the following in adults and pediatric patients:Moderately severe to severe infections of the upper-respiratory tract, scarlet fever, erysipelas, and skin and soft-tissue infections due to susceptible streptococci.NOTE: Streptococci in Groups A, C, G, H, L, and M are very sensitive to penicillin G. Other groups, including Group D (enterococci), are resistant. Penicillin G sodium or potassium is recommended for streptococcal infections with bacteremia.Moderately severe pneumonia and otitis media due to susceptible Streptococcus pneumoniae.NOTE: Severe pneumonia, empyema, bacteremia, pericarditis, meningitis, peritonitis, and arthritis of pneumococcal etiology are better treated with penicillin G sodium or potassium during the acute stage.When high, sustained serum levels are required, penicillin G sodium or potassium, either IM or IV, should be used. This drug should not be used in the treatment of venereal diseases, including syphilis, gonorrhea, yaws, bejel, and pinta.

Regulatory & Marketing

Labeler Name
Dispensing Solutions, Inc.
FDA Application #
NDA050138
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
05-18-1953
Listing Expiration
12-31-2017
Exclude Flag
I
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 68258-8910-2 identifies a specific commercial package of 2 ml in 1 syringe of Bicillin Cr, labeled by Dispensing Solutions, Inc.. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Dispensing Solutions, Inc. on May 18, 1953. The current certification is valid through December 31, 2017.

How is this Dispensing Solutions, Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 68258891002. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-4-1)
68258-8910-2
11-Digit CMS (5-4-2)
68258-8910-02

Note: The zero is added to the Package segment to maintain the 5-4-2 structure.